| 生物活性 | MOTS-c (human) is a mitochondria-derived peptide capable of crossing the blood-brain barrier that enhances insulin sensitivity by regulating the AMPK/PGC-1α pathway, and inhibits the folate cycle and de novo purine synthesis, elevating AICAR levels to activate AMPK, thereby modulating the Nrf2/Keap1 antioxidant pathway and suppressing the NF-κB inflammatory pathway while promoting mitochondrial biogenesis and energy metabolism; it possesses effects of improving glucose and lipid metabolism, antioxidant stress, anti-inflammation, and neuroprotection, and can be used for research on type 2 diabetes, traumatic brain injury, inflammatory diseases, and aging-related metabolic disorders (recent advances in high-resolution sequencing have led to the discovery of unique peptides derived from the mitochondrial genome, and 8 peptides have been identified to date: humanin, the mitochondrial open reading frame of 12S tRNA-c (MOTS-c), and 6 small peptides (humanin-like peptides (SHLP1-6)), all of which are released from mitochondria into the cytoplasm and are associated with extended lifespan and cell viability, reduced apoptosis, and other beneficial functions). | ||||||||||||||||||||||||
| IC50 & Target |
|
||||||||||||||||||||||||
| 体外研究 (In Vitro) |
基于高分辨率测序技术的应用,促成了源自线粒体基因组的独特肽的发现。目前已鉴定出八种肽:人源肽、12S tRNA-c 的线粒体开放阅读框 (MOTS-c) 以及六种短肽 (人源肽样肽 (SHLP1-6))。所有这些肽均从线粒体释放到细胞质中,并与延长寿命和细胞活力、减少细胞凋亡以及其他有益功能相关。 Western Blot Analysis
|
||||||||||||||||||||||||
| 体内研究 (In Vivo) |
MOTS-c (human) (25-50 mg/kg;腹腔注射;每日 1 次;21 天) 在雄性 C57BL/6 小鼠的创伤性脑损伤模型中,可减轻神经功能缺损,抑制脑组织 HMGB1/TLR4/NF-κB 炎症通路。
|
||||||||||||||||||||||||
| 性状 | 固体 | ||||||||||||||||||||||||
| 颜色 | White to off-white |
| 分子量 | 2174.59 |
| 分子式 | C101H152N28O22S2 |
| CAS No. | 1627580-64-6 |
| 储存方式 | Sealed storage, away from moisture
*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
|||||||||||||||||||||||||||||||||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||||||||||||||||||||||
|
溶液配制表
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
H2O 中的溶解度 : ≥ 100 mg/mL (45.99 mM) * "≥" means soluble, but saturation unknown.
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
||||||||||||||||||||||||||||||||||||||||||||||||
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。